Good Practice on the assessment of GMO-related aspects in the context of clinical trials with human cells genetically modified by means of retro/lentiviral vectors, version 5 published by the European Commission in November 2021.

See also: https://ec.europa.eu/health/human-use/advanced-therapies_en